SKYEPHARMA PLC Form 6-K June 12, 2006

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a - 16 OR 15d - 16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

For immediate release

Edgar Filing: SKYEPHARMA PLC - Form 6-K

SkyePharma PLC

SkyePharma (Jersey) Limited £20 million 8 per cent Guaranteed Convertible Bonds due 2025

As a result of the average closing price of SkyePharma PLC shares on 3 June 2006 being less than 75% of the prevailing Exchange Price of the 8% Guaranteed Convertible Bonds due 2025 (77 pence), the Exchange Price has been reset to 58 pence in accordance with the terms and conditions of the bonds.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill Title: Company Secretary

Date: June 12, 2006